FDA Avoids Law Violation By Canceling Secret Meeting On Experimental Blood Substitute

The Food and Drug Administration (FDA) has avoided a major violation of the law today by canceling its scheduled closed July 14 meeting to consider the safety of the blood substitute product known as Hemopure for use in trials involving trauma patients. The FDA’s decision is a de facto admission that the meeting, had it been held in its closed format, would have violated the Federal Advisory Committee Act.

Back to news